Losartan may inhibit the progression of liver fibrosis in chronic HCV patients.
about
The emerging role of mast cells in liver disease.Hepatic stellate cells as key target in liver fibrosis.High-fat diet-induced glucose dysregulation is independent of changes in islet ACE2 in mice.Losartan Alleviates Renal Fibrosis and Inhibits Endothelial-to-Mesenchymal Transition (EMT) Under High-Fat Diet-Induced HyperglycemiaTranscriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology
P2860
Losartan may inhibit the progression of liver fibrosis in chronic HCV patients.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Losartan may inhibit the progression of liver fibrosis in chronic HCV patients.
@en
type
label
Losartan may inhibit the progression of liver fibrosis in chronic HCV patients.
@en
prefLabel
Losartan may inhibit the progression of liver fibrosis in chronic HCV patients.
@en
P2093
P2860
P356
P1476
Losartan may inhibit the progression of liver fibrosis in chronic HCV patients.
@en
P2093
Ahmed M Abdelhady
Ahmed Sadek
Gamal Esmat
Samar Kamal Darweesh
Shereif Ahmed Morsy
Zakaria A Salama
P2860
P304
P356
10.21037/HBSN.2016.02.06
P577
2016-06-01T00:00:00Z